Just a few months after Boehringer Ingelheim broke into the oncology space with the first drug that can target a rare tumor ...
The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.
The first of seven challenges for which Teva is seeking novel solutions revolves around human-predictive platforms for ...
Facing the fact that Lundbeck’s unexpected offer for Avadel was sweeter, Alkermes has come back to the negotiating table with ...
Two months after Celltrion bought a U.S. manufacturing facility from Eli Lilly for roughly $330 million, the South Korean ...
Amid the pharma industry's breakneck onshoring push this past year, North Carolina has been a major beneficiary as investment announcements rolled in from the likes of ...
In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle | ...
When Ali Sullivan enrolled at Indiana University, she thought she wanted to become a speech pathologist. Midway through her college career, however, she changed her mind and her career path. | In a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback